Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 3Genitourinary 2Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Neoplasms 32Neoplasm Metastasis 21Neoplasms by Site 3Carcinoma 3Adenocarcinoma 3Neoplasms, Unknown Primary 1Carcinoma, Squamous Cell 1

Interventions

Nivolumab 3relatlimab 1montanide ISA 51 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms by Site × Nivolumab × Tumor-Agnostic × Clear all
NCT01968109 2026-04-06

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Bristol-Myers Squibb

Phase 1/2 Completed
1,482 enrolled 56 charts
Tumor-Agnostic

Neoplasms by Site

NCT03656718 2025-11-12

A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)

Bristol-Myers Squibb

Phase 1/2 Completed
139 enrolled 26 charts
Tumor-Agnostic

Neoplasms by Site

NCT01629758 2015-03-06

Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors

Bristol-Myers Squibb

Phase 1 Completed
33 enrolled
Tumor-Agnostic

Neoplasms by Site

Data powered by HemOnc (CC BY 4.0) Colophon âš¡